Please login to the form below

Not currently logged in
Email:
Password:

AZ sees Seroquel XR patent overturned in Germany

Follows challenge by Teva, Hexal and Accord Healthcare

Germany flagGermany's Federal Patent Court has ruled a patent for AstraZeneca's antipsychotic Seroquel XR invalid after a challenge by a trio of generic drug companies.

Teva, Hexal and Accord Healthcare successfully persuaded the court to strike out the formulation patent protecting Seroquel XR (quetiapine fumarate) prolonged-release tablets.

This version of the drug is marketed as Seroquel Prolong in Germany, where it brought in $82m in the ten months to October 31, 2012.

“AstraZeneca is disappointed with the court's decision. The company remains committed to defending its intellectual property protecting Seroquel XR,” the firm said in a statement.

Seroquel has faced a number of generic challenges from companies keen to take a slice of global sales from that last year reached $5.8bn for the Seroquel franchise.

When it comes to protecting the extended release (XR) version of its antipsychotic drug AstraZeneca has had mixed results.

In March, a US court ruled the XR patent was valid, deciding that the generics companies Anchen Pharmaceuticals, Osmotica Pharmaceutical, Torrent Pharmaceuticals and Mylan had infringed AZ's patent.

But in the same month the legal situation turned against AZ in its home territory of the UK, where the high court deemed the Seroquel XR patent invalid.

14th November 2012

From: Sales, Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics